Bronchiolitis remains the leading cause of hospital admission in infancy and of paediatric intensive care unit use.1 Management of bronchiolitis has been largely limited to supportive care, reflecting both the complexity of disease pathophysiology and the repeated failure of targeted pharmacological interventions to alter outcomes. Nevertheless, exogenous surfactant therapy is a plausible candidate in the management of severe bronchiolitis because of its parallels with neonatal respiratory distress syndrome, for which surfactant replacement has transformed outcomes for preterm-born infants.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 21 Mar 2026. The item focuses on Surfactant therapy in severe infant bronchiolitis: evidence from the BESS trial. Open the detail page to review the full original feed content.